{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:17:11Z","timestamp":1793654231098,"version":"4.5.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T00:00:00Z","timestamp":1393977600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-153","type":"journal-article","created":{"date-parts":[[2014,3,5]],"date-time":"2014-03-05T05:02:15Z","timestamp":1393995735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Xin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,5]]},"reference":[{"key":"5213_CR1","doi-asserted-by":"crossref","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997, 89 (11): 3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"issue":"1","key":"5213_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62 (1): 10-29. 10.3322\/caac.20138.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"5213_CR3","first-page":"193","volume":"158","author":"T Sattar","year":"2006","unstructured":"Sattar T, Griffeth LK, Latifi HR, Glass J, Munker R, Lilien DL: PET imaging today: contribution to the initial staging and prognosis of patients with non-Hodgkin\u2019s lymphomas. J La State Med Soc. 2006, 158 (4): 193-201.","journal-title":"J La State Med Soc"},{"issue":"3","key":"5213_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1083\/jcb.123.3.513","volume":"123","author":"C Schluter","year":"1993","unstructured":"Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993, 123 (3): 513-522. 10.1083\/jcb.123.3.513.","journal-title":"J Cell Biol"},{"issue":"1","key":"5213_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/PAS.0b013e31826731b5","volume":"37","author":"S Li","year":"2013","unstructured":"Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, Konoplev S, Bueso-Ramos CE, Vega F, Medeiros LJ, Yin CC: Extranodal NK\/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol. 2013, 37 (1): 14-23. 10.1097\/PAS.0b013e31826731b5.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"5213_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E: Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u2009+\u2009autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012, 158 (3): 355-362. 10.1111\/j.1365-2141.2012.09174.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"5213_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1600-0609.2012.01778.x","volume":"88","author":"ZM Li","year":"2012","unstructured":"Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ: High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol. 2012, 88 (6): 510-517. 10.1111\/j.1600-0609.2012.01778.x.","journal-title":"Eur J Haematol"},{"issue":"7","key":"5213_CR8","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.3109\/10428194.2010.483302","volume":"51","author":"A Goy","year":"2010","unstructured":"Goy A, Bernstein SH, McDonald A, Pickard MD, Shi H, Fleming MD, Bryant B, Trepicchio W, Fisher RI, Boral AL, Mulligan G: Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma. 2010, 51 (7): 1269-1277. 10.3109\/10428194.2010.483302.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"5213_CR9","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00277-004-0855-x","volume":"83","author":"M Jerkeman","year":"2004","unstructured":"Jerkeman M, Anderson H, Dictor M, Kvaloy S, Akerman M, Cavallin-Stahl E: Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma\u2013a Nordic Lymphoma Group study. Ann Hematol. 2004, 83 (7): 414-419. 10.1007\/s00277-004-0855-x.","journal-title":"Ann Hematol"},{"issue":"8","key":"5213_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1080\/10428190802140055","volume":"49","author":"S Hasselblom","year":"2008","unstructured":"Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H, Andersson PO: Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma. 2008, 49 (8): 1501-1509. 10.1080\/10428190802140055.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"5213_CR11","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007, 109 (5): 1857-1861. 10.1182\/blood-2006-08-038257.","journal-title":"Blood"},{"issue":"5","key":"5213_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1470-2045(08)70078-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E: Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008, 9 (5): 435-444. 10.1016\/S1470-2045(08)70078-0.","journal-title":"Lancet Oncol"},{"issue":"10","key":"5213_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009, 62 (10): 1006-1012. 10.1016\/j.jclinepi.2009.06.005.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"5213_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25 (9): 603-605. 10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"24","key":"5213_CR15","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998, 17 (24): 2815-2834. 10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8.","journal-title":"Stat Med"},{"issue":"6","key":"5213_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.apmr.2006.04.006","volume":"87","author":"HH Handoll","year":"2006","unstructured":"Handoll HH: Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil. 2006, 87 (6): 875-10.1016\/j.apmr.2006.04.006.","journal-title":"Arch Phys Med Rehabil"},{"issue":"7414","key":"5213_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ. 2003, 327 (7414): 557-560. 10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"4","key":"5213_CR18","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22 (4): 719-748.","journal-title":"J Natl Cancer Inst"},{"issue":"26","key":"5213_CR19","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","volume":"117","author":"G Salles","year":"2011","unstructured":"Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Calaminici M, Sander B, Thorns C, Campo E, Molina T, Lee A, Pfreundschuh M, Horning S, Lister A, Sehn LH, Raemaekers J, Hagenbeek A, Gascoyne RD, Weller E: Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011, 117 (26): 7070-7078. 10.1182\/blood-2011-04-345256.","journal-title":"Blood"},{"issue":"1","key":"5213_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000324206","volume":"126","author":"F Gaudio","year":"2011","unstructured":"Gaudio F, Giordano A, Perrone T, Pastore D, Curci P, Delia M, Napoli A, De\u2019 Risi C, Spina A, Ricco R, Liso V, Specchia G: High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol. 2011, 126 (1): 44-51. 10.1159\/000324206.","journal-title":"Acta Haematol"},{"issue":"3","key":"5213_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11060-011-0555-z","volume":"104","author":"MK Song","year":"2011","unstructured":"Song MK, Chung JS, Joo YD, Lee SM, Oh SY, Shin DH, Yun EY, Kim SG, Seol YM, Shin HJ, Choi YJ, Cho GJ: Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma. J Neurooncol. 2011, 104 (3): 825-831. 10.1007\/s11060-011-0555-z.","journal-title":"J Neurooncol"},{"issue":"23","key":"5213_CR22","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","volume":"116","author":"G Ott","year":"2010","unstructured":"Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, Thorns C, Feller AC, Lenze D, Hummel M, Stein H, Muller-Hermelink HK, Frank M, Hansmann ML, Barth TF, Moller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trumper L, Loeffler M, Rosenwald A: Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010, 116 (23): 4916-4925. 10.1182\/blood-2010-03-276766.","journal-title":"Blood"},{"issue":"8","key":"5213_CR23","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3109\/10428194.2010.489243","volume":"51","author":"MH Barros","year":"2010","unstructured":"Barros MH, Scheliga A, De Matteo E, Minnicelli C, Soares FA, Zalcberg IR, Hassan R: Cell cycle characteristics and Epstein-Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients. Leuk Lymphoma. 2010, 51 (8): 1513-1522. 10.3109\/10428194.2010.489243.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"5213_CR24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0609.2010.01467.x","volume":"85","author":"DH Yoon","year":"2010","unstructured":"Yoon DH, Choi DR, Ahn HJ, Kim S, Lee DH, Kim SW, Park BH, Yoon SO, Huh J, Lee SW, Suh C: Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol. 2010, 85 (2): 149-157.","journal-title":"Eur J Haematol"},{"issue":"3","key":"5213_CR25","first-page":"244","volume":"3","author":"R Chung","year":"2010","unstructured":"Chung R, Peters AC, Armanious H, Anand M, Gelebart P, Lai R: Biological and clinical significance of GSK-3beta in mantle cell lymphoma\u2013an immunohistochemical study. Int J Clin Exp Pathol. 2010, 3 (3): 244-253.","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"5213_CR26","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/cncr.24141","volume":"115","author":"M Garcia","year":"2009","unstructured":"Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ: Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer. 2009, 115 (5): 1041-1048. 10.1002\/cncr.24141.","journal-title":"Cancer"},{"issue":"11","key":"5213_CR27","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1080\/10428190802419640","volume":"49","author":"ED Hsi","year":"2008","unstructured":"Hsi ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD, Damon LE, Said J: Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma. 2008, 49 (11): 2081-2090. 10.1080\/10428190802419640.","journal-title":"Leuk Lymphoma"},{"issue":"2A","key":"5213_CR28","first-page":"1113","volume":"28","author":"K Szczuraszek","year":"2008","unstructured":"Szczuraszek K, Mazur G, Jelen M, Dziegiel P, Surowiak P, Zabel M: Prognostic significance of Ki-67 antigen expression in non-Hodgkin\u2019s lymphomas. Anticancer Res. 2008, 28 (2A): 1113-1118.","journal-title":"Anticancer Res"},{"issue":"4","key":"5213_CR29","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, Barth TE, Unterhalt M, Hiddemann W, Dreyling M, Klapper W: Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008, 111 (4): 2385-2387. 10.1182\/blood-2007-10-117010.","journal-title":"Blood"},{"issue":"8","key":"5213_CR30","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/annonc\/mdm183","volume":"18","author":"SJ Kim","year":"2007","unstructured":"Kim SJ, Kim BS, Choi CW, Choi J, Kim I, Lee YH, Kim JS: Ki-67 expression is predictive of prognosis in patients with stage I\/II extranodal NK\/T-cell lymphoma, nasal type. Ann Oncol. 2007, 18 (8): 1382-1387. 10.1093\/annonc\/mdm183.","journal-title":"Ann Oncol"},{"issue":"5","key":"5213_CR31","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2559.2006.02377.x","volume":"48","author":"AA Bahnassy","year":"2006","unstructured":"Bahnassy AA, Zekri AR, Asaad N, El-Houssini S, Khalid HM, Sedky LM, Mokhtar NM: Epstein-Barr viral infection in extranodal lymphoma of the head and neck: correlation with prognosis and response to treatment. Histopathology. 2006, 48 (5): 516-528. 10.1111\/j.1365-2559.2006.02377.x.","journal-title":"Histopathology"},{"issue":"2","key":"5213_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0002-9440(10)63140-9","volume":"164","author":"A Martinez","year":"2004","unstructured":"Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N, Ott G, Montserrat E, Campo E, Colomer D: Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004, 164 (2): 501-510. 10.1016\/S0002-9440(10)63140-9.","journal-title":"Am J Pathol"},{"issue":"4","key":"5213_CR33","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ajh.10379","volume":"73","author":"R Seki","year":"2003","unstructured":"Seki R, Okamura T, Koga H, Yakushiji K, Hashiguchi M, Yoshimoto K, Ogata H, Imamura R, Nakashima Y, Kage M, Ueno T, Sata M: Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003, 73 (4): 230-235. 10.1002\/ajh.10379.","journal-title":"Am J Hematol"},{"issue":"4","key":"5213_CR34","first-page":"1406","volume":"9","author":"M Provencio","year":"2003","unstructured":"Provencio M, Corbacho C, Salas C, Millan I, Espana P, Bonilla F, Ramon Cajal S: The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin\u2019s lymphoma. Clin Cancer Res. 2003, 9 (4): 1406-1411.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5213_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","volume":"69","author":"R Raty","year":"2002","unstructured":"Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E: Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol. 2002, 69 (1): 11-20. 10.1034\/j.1600-0609.2002.01677.x.","journal-title":"Eur J Haematol"},{"issue":"5","key":"5213_CR36","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1200\/JCO.1998.16.5.1931","volume":"16","author":"E Sanchez","year":"1998","unstructured":"Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF, Piris MA: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol. 1998, 16 (5): 1931-1939.","journal-title":"J Clin Oncol"},{"issue":"6","key":"5213_CR37","first-page":"2429","volume":"90","author":"MM Morente","year":"1997","unstructured":"Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, Garcia-Del-Moral R, Gomez-Marcos F, Menarguez J, Oliva H, Sanchez-Beato M, Montalban C: Adverse clinical outcome in Hodgkin\u2019s disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood. 1997, 90 (6): 2429-2436.","journal-title":"Blood"},{"issue":"6","key":"5213_CR38","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V83.6.1460.1460","volume":"83","author":"TP Miller","year":"1994","unstructured":"Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin\u2019s lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994, 83 (6): 1460-1466.","journal-title":"Blood"},{"issue":"6","key":"5213_CR39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.1990.8.6.986","volume":"8","author":"DJ Slymen","year":"1990","unstructured":"Slymen DJ, Miller TP, Lippman SM, Spier CM, Kerrigan DP, Rybski JA, Rangel CS, Richter LC, Grogan TM: Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. J Clin Oncol. 1990, 8 (6): 986-993.","journal-title":"J Clin Oncol"},{"key":"5213_CR40","volume-title":"Leuk Lymphoma","author":"D Salek","year":"2013","unstructured":"Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S, Jankovska M, Pytlik R, Belada D, Pirnos J, Moulis M, Kodet R, Michal M, Janousova E, Muzik J, Mayer J, Trneny M: Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leuk Lymphoma. 2013"},{"issue":"4","key":"5213_CR41","first-page":"867","volume":"138","author":"J Gerdes","year":"1991","unstructured":"Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991, 138 (4): 867-873.","journal-title":"Am J Pathol"},{"issue":"1","key":"5213_CR42","first-page":"83","volume":"20","author":"P Dziegiel","year":"2005","unstructured":"Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A, Zabel M: Prognostic significance of augmented metallothionein (MT) expression correlated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol. 2005, 20 (1): 83-89.","journal-title":"Histol Histopathol"},{"issue":"28","key":"5213_CR43","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","volume":"23","author":"A Urruticoechea","year":"2005","unstructured":"Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005, 23 (28): 7212-7220. 10.1200\/JCO.2005.07.501.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5213_CR44","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1002\/cncr.10458","volume":"94","author":"F Spyratos","year":"2002","unstructured":"Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V: Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer. 2002, 94 (8): 2151-2159. 10.1002\/cncr.10458.","journal-title":"Cancer"},{"issue":"2","key":"5213_CR45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.V89.2.601","volume":"89","author":"WH Wilson","year":"1997","unstructured":"Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M: Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin\u2019s lymphomas. Blood. 1997, 89 (2): 601-609.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-153\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T16:20:19Z","timestamp":1716567619000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5213"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-153","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,5]]},"assertion":[{"value":"13 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"153"}}